Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. Concurrent with the acquisition of Quellis, Catabasis entered into a definitive agreement for the sale of Series X convertible preferred stock (the “Series X preferred stock”) in a private placement to a group of institutional accredited investors led by Perceptive Advisors.
Read the full article: Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc. //
Source: https://www.businesswire.com/news/home/20210129005080/en/Catabasis-Pharmaceuticals-Announces-Acquisition-of-Quellis-Biosciences-Inc.